Alaunos Therapeutics, Inc.

NASDAQ:TCRT

2.02 (USD) • At close November 7, 2024
Bedrijfsnaam Alaunos Therapeutics, Inc.
Symbool TCRT
Munteenheid USD
Prijs 2.02
Beurswaarde 3,234,525
Dividendpercentage 0%
52-weken bereik 2 - 33
Industrie Biotechnology
Sector Healthcare
CEO Mr. Kevin S. Boyle Sr.
Website https://www.alaunos.com

An error occurred while fetching data.

Over Alaunos Therapeutics, Inc.

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic,

Vergelijkbare Aandelen

TELA Bio, Inc. logo

TELA Bio, Inc.

TELA

2.99 USD

Candel Therapeutics, Inc. logo

Candel Therapeutics, Inc.

CADL

5.09 USD

Champions Oncology, Inc. logo

Champions Oncology, Inc.

CSBR

4.32 USD

Immuneering Corporation logo

Immuneering Corporation

IMRX

1.93 USD

Leap Therapeutics, Inc. logo

Leap Therapeutics, Inc.

LPTX

3.47 USD

Anixa Biosciences, Inc. logo

Anixa Biosciences, Inc.

ANIX

3.62 USD

KORU Medical Systems, Inc. logo

KORU Medical Systems, Inc.

KRMD

2.82 USD

Achilles Therapeutics plc logo

Achilles Therapeutics plc

ACHL

1.045 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)